Wall Street analysts predict that CareDx, Inc. (NASDAQ:CDNA) will post $11.87 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for CareDx’s earnings. The highest sales estimate is $12.08 million and the lowest is $11.65 million. CareDx posted sales of $10.71 million in the same quarter last year, which would indicate a positive year over year growth rate of 10.8%. The firm is scheduled to announce its next earnings report on Wednesday, August 9th.

According to Zacks, analysts expect that CareDx will report full year sales of $11.87 million for the current year, with estimates ranging from $46.65 million to $46.70 million. For the next year, analysts forecast that the company will post sales of $55.20 million per share. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for CareDx.

A number of brokerages have recently commented on CDNA. ValuEngine lowered CareDx from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Zacks Investment Research lowered CareDx from a “buy” rating to a “hold” rating in a report on Thursday, June 8th.

Shares of CareDx (NASDAQ CDNA) remained flat at $1.30 on Friday. The stock had a trading volume of 51,545 shares. The company’s market cap is $27.85 million. The firm’s 50-day moving average price is $1.15 and its 200 day moving average price is $1.61. CareDx has a 52-week low of $0.76 and a 52-week high of $5.06.

TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/07/22/11-87-million-in-sales-expected-for-caredx-inc-nasdaqcdna-this-quarter.html.

In related news, major shareholder Neil Gagnon bought 63,120 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The shares were acquired at an average price of $1.10 per share, for a total transaction of $69,432.00. Following the completion of the acquisition, the insider now owns 886,216 shares of the company’s stock, valued at approximately $974,837.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders bought 94,319 shares of company stock worth $99,441. Corporate insiders own 5.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in CDNA. Armstrong Henry H Associates Inc. bought a new stake in CareDx during the first quarter valued at about $22,450,000. Gagnon Securities LLC raised its stake in CareDx by 12.8% in the first quarter. Gagnon Securities LLC now owns 2,026,338 shares of the company’s stock valued at $2,837,000 after buying an additional 230,494 shares during the last quarter. Finally, Royce & Associates LP raised its stake in CareDx by 23.5% in the first quarter. Royce & Associates LP now owns 526,472 shares of the company’s stock valued at $737,000 after buying an additional 100,111 shares during the last quarter. Institutional investors and hedge funds own 36.52% of the company’s stock.

About CareDx

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Get a free copy of the Zacks research report on CareDx (CDNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.